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Abstract: Natural ribonucleoside-5’-monophosphates are building blocks for nucleic acids which
are used for a number of purposes, including food additives. Their analogues, additionally,
are used in pharmaceutical applications. Fludarabine-5´-monophosphate, for example, is effective
in treating hematological malignancies. To date, ribonucleoside-5’-monophosphates are mainly
produced by chemical synthesis, but the inherent drawbacks of this approach have led to
the development of enzymatic synthesis routes. In this study, we evaluated the potential of
human deoxycytidine kinase (HsdCK) as suitable biocatalyst for the synthesis of natural and
modified ribonucleoside-5’-monophosphates from their corresponding nucleosides. Human dCK
was heterologously expressed in E. coli and immobilized onto Nickel-nitrilotriacetic acid (Ni-NTA)
superflow. A screening of the substrate spectrum of soluble and immobilized biocatalyst revealed
that HsdCK accepts a wide range of natural and modified nucleosides, except for thymidine and
uridine derivatives. Upon optimization of the reaction conditions, HsdCK was used for the synthesis
of fludarabine-5´-monophosphate using increasing substrate concentrations. While the soluble
biocatalyst revealed highest product formation with the lowest substrate concentration of 0.3 mM, the
product yield increased with increasing substrate concentrations in the presence of the immobilized
HsdCK. Hence, the application of immobilized HsdCK is advantageous upon using high substrate
concentration which is relevant in industrial applications.
Keywords: human deoxycytidine kinase; Ni-NTA sepharose; activity screening; nucleoside analogue;
cladribine; clofarabine; fludarabine
1. Introduction
Modified nucleosides and nucleotides are important small molecules in molecular, biological
and pharmaceutical applications. Since they are involved in the same metabolic pathways
as endogenous nucleosides and nucleotides, they act as antimetabolites, thus, exerting useful
pharmacological action [1]. Most of the known nucleoside analogue drugs are activated in vivo to
their respective active forms (nucleoside-5’-diphosphate or nucleoside-5’-triphosphate), nevertheless,
in vivo activation is often insufficient [2]. Therefore, in a number of approaches, bio-reversible protected
ribonucleoside-5’-monophosphates (NMPs), such as the phosphoramidate prodrug sofosbuvir were
administered to overcome the first activation step in vivo [3–6].
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To date, nucleotides are mainly produced by chemical methods like the Yoshikawa protocol or the
Ludwig-Eckstein method [7]. A common disadvantage of these multistep chemical synthesis reactions
is a limited regio- and stereo-selectivity leading to a need for protection/deprotection steps. Several
side products are produced, which in return complicates the purification process. The overall process
is laborious, and often only moderate product yields are achieved. Furthermore, nucleotide products
harboring sensitive functional groups, such as a triazide ring cannot be synthesized at all in a chemical
approach, as they cannot withstand the harsh conditions [8].
Despite the progress made in the optimization of chemical synthesis routes, enzymatic or
chemo-enzymatic methods are often a good alternative [9]. Compared to chemical synthesis routes,
biotransformation usually does not require protection or deprotection steps and lead to high final
product yields, due to the high regio- and stereo-selectivity of the enzymes. Deoxyribonucleoside
kinases were described as suitable biocatalysts for the synthesis of nucleotide analogues [10,11].
As an example, the deoxynucleoside kinase (dNK) from the fruit-fly Drosophila melanogaster was
shown to have a wide substrate spectrum and to use 2’-deoxy-ribonucleosides, arabinosyl-uracil,
arabinosyl-adenine and fludarabine as substrates [11].
Human deoxycytidine kinase (HsdCK) is another interesting biocatalyst for the synthesis of
nucleotide analogues. In vivo, it plays an important role in maintaining the homeostasis of the
2’-deoxy-ribonucleotide pool within the cell. Using adenosine triphosphate or uridine triphosphate
as a phosphate donor, it catalyzes the 5′-phosphorylation of deoxycytidine, deoxyadenosine, and
deoxyguanosine [12–15]. Furthermore, dCK activity is essential for the activation of a wide variety of
important therapeutic prodrugs, such as the antiviral agent lamivudine (3TC), for the treatment of HIV
infection [16], or antineoplastic agents like cladribine [17] (Scheme 1).
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Both whole immobilized cells and purified enzymes have been used for the synthesis of
NMP analogues [18,19]. Immobilization techniques help to stabilize biocatal sts under harsh
conditions (e.g., high temperatur , extreme pH, solvents) [19]. As the immobilized biocatalysts
can be used re atedly the processes get more cost-effectiv , which s an important consideration for
industrial applications. Using dNK and d oxyadenosine ki ase (dAK) of Drosophila melanogaster and
Dictyostelium di coideum, respectiv ly, fludarabi -5’-monophosphate (2F-AraAMP) was synthesized
from fludarabine (2F-AraA) with a high conversion percentage (> 90%) [10,11].
In this study, the chemo-enzymatic synthesis of NMP nalogues from nucleosides using soluble
and immobilized HsdCK is demonstrated (Scheme 2). HsdCK was chosen as it is a well-studi d
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enzyme showing a wide substrate spectrum. However, it is potential for industrial application was not
studied so far. Nickel-nitrilotriacetic acid (Ni-NTA) superflow was applied as the support, since the
applied enzymes bear an N-terminal His-tag and it is described as a gentle way of immobilization.
Enzyme immobilization did not influence the substrate spectrum of HsdCK. It was shown that HsdCK
is a valuable biocatalyst for the synthesis of NMP analogues. Compared to the soluble biocatalyst,
immobilized HsdCK showed increased efficiency with increasing substrate concentration.
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2. Results
2.1. Production of Soluble and Immobilized HsdCK
After expression in a fed-batch medium in shake flasks, HsdCK was either immobilized onto
Ni-NTA superflow resin or produced as a soluble enzyme by elution from Ni-NTA superflow material
(Figure 1A, Figure S1). Three independent enzyme immobilizations/purification experiments were
performed with five replicas for each experiment. While three replicates were used as immobilized
biocatalysts, two replicas were used for protein elution to estimate the amount of bound enzyme and
to be later used as a soluble biocatalyst for the synthesis of nucleotide analogues.
In preliminary experiments, the amount of cell pellet loaded to the matrix was optimized.
When loading the lysate prepared of 0.5 g of cell pellet to 100 µl of the matrix and using 500 µl of elution
buffer, the protein concentration in each elution fraction was below 0.5 mg mL−1 (Figure S2). This was
insufficient for further experiments. Hence, lysate derived from 1.5 g of cell pellet was loaded, and the
volume of elution buffer was reduced to 100 µL. By using this protocol protein, the concentrations
strongly increased.
Protein concentrations were measured by NanoDrop at 280 nm. Protein concentration in the soluble
fraction of the cell extract was around 46 mg mL−1. In the elution fractions, protein concentrations
between 1 mg mL−1 to 5.5 mg mL−1 were determined (Figure 1B). Highest protein concentrations were
observed in the first elution fraction for all immobilization experiments. The total amount of protein
bound to 100 µl of the matrix was between 0.5 (experiment 3) to 1.2 mg (experiment 1). The amount
of bound protein was comparable within the replicates of one immobilization (Figure 1C). However,
differences were observed between the different immobilization experiments. This observation is
probably caused by using different cell pellets for each immobilization experiment. Therefore, it was
necessary to determine the amount of bound protein for each immobilization experiment.
Samples obtained from the elution fractions were analyzed by SDS-PAGE and expression of
HsdCK in the lysate of cell extract was verified (Figure 1B). For all immobilization experiments, purified
HsdCK was detected in the elution fractions, and only a few and comparable impurities were observed.
Purity was estimated to be approximately 90%.
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Figure 1. Im obilization of HsdCK to Ni-NTA superflow via affinity interaction. (A) The strategy used
for each immobilization experiment with HsdCK. After expr ssion in Enpresso B medium, cells were
disrupted by enzymatic and mechanical lysis. Each immob lization experiment was perform d with five
replicas. Two replicas were used for protein elution. (B) Protein conc ntrations in the elution fractions
we e determined by NanoDrop measu ements. The amount of the to ally bound protein was calcul ted.
Standard deviations were calculated from two replicas of the eluted prot in. (C) The purification
process was validated by SDS-PAGE. The two replicas of immobilization experiment 1 are p esented as
an example. The target protein is ighli hted by an arrow (34.5 KDa). sExtract—soluble fraction of the
cell extract; FT—flow through; W1-W3—washing fractions; E1-E3—elution fractions.
2.2. Enzymatic Synthesis of NMP Analogues
Soluble and immobilized HsdCK were tested for their substrate spectrum with a variety of
natural and modified nucleosides (Figure 2). Th screening assay was appli d as a qualit tive measure.
Reactions were analyzed after 20 h to guarantee product formation even with poor substrates.
The stability of the soluble and immobilized biocatalyst and the phosphate donor (GTP) was studied in
advance. After incubating HsdCK for 24 h at 37 ◦C, no influence on deoxycytidine-5’-monophosphate
formation was observed using reaction times of 24 h (Figure S3A). No impact on the stability of the
phosphate donors was observed by incubating them for 24 h at 37 ◦C (Figure S3B,C).
Using soluble and immobilized HsdCK, natural deoxynucleosides were converted to their
equivalent 5’-monophosphate except for thymidine and deoxyuridine (Figure 2A). These two were not
accepted as a substrate by HsdCK. While the percentage of conversion was approximately 100% using
soluble HsdCK, it was between 20% to 40% with the immobilized biocatalyst.
Additionally, a wide variety of modified nucleosides were accepted as substrates, including
cytarabine, cladribine, fludarabine, clofarabine and gemcitabine (Figure 2B). With arabinosyl-adenine,
azacytidine and lamivudine, lower product formation was observed. Nucleosides harboring a thymine
or modified uracil base (zidovudine, stavudine and iodoxuridine) were not accepted by heterologously
expressed HsdCK. In general, the same trend was observed with both the immobilized and the soluble
biocatalyst; however, conversion with immobilized enzyme was mainly lower (Figure 2).
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Figure 2. Substrate spectrum of human dCK with natural (A) and modified (B) nucleosides as substrates.
Reactions were performed in 2 mM potassiu phosphate buffer pH 7 with 10 mM MgCl2, 0.4 m of GTP
and 0.333 mM of substrate in a reaction volume of 0.5 mL. A reaction temperature of 37 ◦C was used. 0.01
mg mL−1 of the enzyme was added to the reaction. The reactions were analyzed after a reaction time of 20
h. dThd—deoxythymidine, dCyd—deoxycytidine, dAdo—deoxyadenosine, dGuo—deoxyguanosine,
dUrd—deoxyuridine, dIno—deoxyinosine, AraA—arabinosyladenine (vidarabine), AZT—zidovudine,
2CldA—2-chlorodeoxyadenosine (cladribine), 2F-AraA—2-fluoroarabinoadenosine (fludarabine),
STV—stavudine, Azacyd—5-azacytidine (azadine), GCT—gemcitabine, AraC—arabinosylcytosine
(cytabrabine), 3TC—lamivudine, IdU—idoxuridine, ClFaraA—2-chloro-2’-fluoroarabinoadenosine
(clofarabine). Mean values and standard deviations were calculated from duplicate reactions of pooled
replicates of immobilization experiment 3.
The impact of immobilization of HsdCK to Ni-NTA sepharose was studied in more detail.
Therefore, specific activities and product formation were determined for cladribine, fludarabine and
clofarabine phosphorylation reactions. When analyzing specific activities determined for cladribine,
fludarabine and clofarabine, higher values were observed for the soluble enzyme compared to the
immobilized enzyme (Table 1). Comparable values were observed for cladribine and fludarabine.
Specific activity was lowest with clofarabine as substrate. Matrix-bound-enzyme activity was between
0.76 U mL−1 (clofarabine) to 1.15 U mL−1 (fludarabine) (Table S1).
Table 1. Phosphorylation of nucleoside analogues cladribine, fludarabine and clofarabine by HsdCK.
Specific activity and percentage of conversion were determined. Reactions were performed in 2 mM
potassium phosphate buffer (pH 7) with 10 mM MgCl2, 0.4 mM of GTP and 0.333 mM of substrate in
a reaction volume of 1 mL. A reaction temperature of 37 ◦C was used. 0.01 mg mL−1 of the enzyme
was added to the reaction. The reactions were monitored over a period of 60 min. Mean values and
standard deviations were calculated for each of the three replicas of immobilization experiment 3.
Substrate Enzyme Specific Activity
[U mg−1]
Retained Activity
[%] Conversion [%]
Cladribine immobilized 0.22 (±0.06) 67 52 (±1)
soluble 0.33 (±0.04) 62 (±3)
Fludarabine immobilized 0.24 (±0.18) 41 25 (±6)
soluble 0.58 (±0.10) 46 (±7)
Clofarabine immobilized 0.16 (±0.03) 84 36 (±6)
soluble 0.19 (±0.03) 38 (±2)
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The impact of immobilization on the percentage of conversion was more pronounced for cladribine
and fludarabine, while differences were minor for clofarabine (Table 1). For the soluble HsdCK,
percentage of conversion increased in the order: clofarabine (62%), fludarabine (46%), cladribine (38)
(Table 1). With the immobilized biocatalyst, the highest percentage of conversion was obtained with
cladribine as well. However, in contrast to the soluble enzyme, conversion was higher for clofarabine
compared to fludarabine.
The retained activity was determined based on the specific activity determined for the soluble
and the immobilized HsdCK (Table 1). Retained activity differed for the different substrates tested.
Retained activity was lowest for fludarabine (41%) and highest for clofarabine (84%).
2.3. Optimization of the Reaction Conditions
As fludarabine-5´-phosphate is an approved drug used to treat hematological malignancies; we
intended to optimize the reaction conditions for its synthesis. Using the standard reaction conditions
and a reaction duration of 1 h, product yields of 21% and 54% were observed using immobilized
and soluble HsdCK as biocatalyst, respectively (Table 2). In order to increase the product yield, the
influence of the phosphate donor, the MgCl2 concentration and the ratio of phosphate donor to the
substrate was analyzed.
Table 2. Phosphorylation of fludarabine using different reaction conditions. The impact of phosphate
donor and varying phosphate donor and MgCl2 concentration on the product formation was studied.
Reactions were performed in 2 mM potassium phosphate buffer (pH 7) in a reaction volume of 1 mL.
A reaction temperature of 37 ◦C was used. 0.01 mg mL−1 of the enzyme was added to the reaction.
The reactions were monitored over a period of 60 min. Mean values and standard deviations were
calculated from two independent experiments performed with pooled replicas of immobilization
experiment 3.
Fludarabine (mM) Phosphate Donor MgCl2 (mM) Enzyme
Conversion %
(Standard Deviation)
Standard reaction condition
0.333 GTP—0.4 mM 10 mM immobilized 21 (0.6)
0.333 GTP—0.4 mM 10 mM soluble 54 (0.4)
Impact of phosphate donor
0.333 ATP—0.4 mM 10 mM immobilized 35 (0.8)
0.333 ATP—0.4 mM 10 mM soluble 53 (0.7)
0.333 UTP—0.4 mM 10 mM immobilized 3 (0.8)
0.333 UTP—0.4 mM 10 mM soluble 13 (0.9)
Impact of ratio of substrate to phosphate donor
0.4 GTP—0.4 mM 10 mM immobilized 21 (0.1)
0.4 GTP—0.4 mM 10 mM soluble 49 (1.6)
0.2 GTP—0.4 mM 10 mM immobilized 16 (1.4)
0.2 GTP—0.4 mM 10 mM soluble 58 (2.1)
0.1 GTP—0.4 mM 10 mM immobilized 12 (0.9)
0.1 GTP—0.4 mM 10 mM soluble 75 (0.3)
Impact of MgCl2 concentration
0.333 GTP—0.4 mM 0.4 mM immobilized 18 (0.5)
0.333 GTP—0.4 mM 0.4 mM soluble 51 (1)
0.333 GTP—0.4 mM 1 mM immobilized 19 (0.7)
0.333 GTP—0.4 mM 1 mM soluble 51 (0.1)
0.333 GTP—0.4 mM 2 mM immobilized 22 (1.1)
0.333 GTP—0.4 mM 2 mM soluble 53 (0.7)
Ericksson and Wang showed that uridine triphosphate (UTP) is likely to be the major intracellular
phosphate donor for HsdCK [20]. Hence, it was expected that UTP is a better phosphate donor compared
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to adenosine triphosphate (ATP). We studied the impact of guanosine triphosphate (GTP), ATP and
UTP on the conversion of fludarabine using heterologously expressed HsdCK. While the conversion
percentages were comparable for both ATP and GTP, fludarabine-5’-monophosphate formation was
significantly less using UTP as the phosphate donor. Only 13% and 3% conversion percentages were
observed using soluble and immobilized HsdCK, respectively. Hence, conversion percentages were
reduced by a factor of 4% to 7%. As comparable results were obtained for both GTP and ATP, further
experiments were performed with GTP.
The molar ratio of fludarabine and GTP was analyzed further. If the soluble protein is considered
first, a higher molar ratio of GTP led to increased conversion of fludarabine (Table 2). The lowest
conversion of 49% was achieved with an equimolar concentration of fludarabine and GTP, when using
a 4-fold excess of GTP, the conversion was 75% after a reaction time of one hour. In contrast, with the
immobilized biocatalyst, we found that the percentage of conversion decreased with increasing excess
of GTP. While the conversion was 21% with molar ratios of fludarabine to GTP of 1:1 and 1:1.2,
the conversion was only 12% with a 4-fold excess of GTP (Table 2). For up-scaling experiments, a molar
ratio of 1:1.2 was used to meet the requirements for reactions with both soluble and immobilized HsdCK.
Magnesium is essential for catalysis involving nucleotides [21]. Therefore, the impact of different
MgCl2 concentrations on the conversion of fludarabine was studied. No significant impact was
observed using MgCl2 concentrations between 0.4 to 10 mM (Table 2). Thus, for further experiments,
an MgCl2 concentration of 10 mM was applied.
When comparing the described data with the initial enzyme screening, reaction time has the
strongest impact on the final product yield. In the screening assay, 100% of fludarabine conversion was
determined using a reaction time of 20 h.
2.4. Reusability of Immobilized HsdCK
A huge advantage of biocatalyst immobilization is the possibility of re-using, thus, increase the
efficiency of the catalytic process. The durability of the immobilized HsdCK was tested (Figure 3).
Three consecutive reactions were performed with the same batch of immobilized enzyme. Our results
have shown a slight decrease (17%) of enzyme activity between reaction 1 and 2 as could be denoted
by the decrease in the formation of fludarabine-5´-monophosphate (Figure 3, Figure S4). The relative
formation of fludarabine-5’-monophosphate formation was decreased by approximately 80% in the
third repetition as compared to the first reaction (Figure 3). Losses in enzyme activity after each re-use
are probably caused by detachment of the protein from the matrix which is increasing over time.Catalysts 2019, 9, x FOR PEER REVIEW 8 of 14 
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Figure 3. Reusability of the immobilized HsdCK for the synthesis of fludarabine-5´-monophosphate.
Relative retained activity in three consecutive reactions was determined. Reactions were performed
in 2 mM potassium phosphate buffer (pH 7) with 10 mM MgCl2, 0.4 mM of GTP and 0.333 mM of
substrate in a reaction volume of 1 mL using a reaction time of 3 h for each reaction. Mean values
and standard deviations were calculated from triplicate reactions performed with pooled replicas of
immobilization experiment 3.
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2.5. Impact of Increasing Substrate Concentrations on HsdCK-Catalyzed Reactions
For industrial application, it is very important to test the possibility to upscale the enzymatic
reaction. Therefore, increasing substrate concentrations (3- to 36-fold) were applied in combination
with increasing biocatalyst concentrations in HsdCK catalyzed reactions. Compared to the standard
reaction conditions, the percentage of formation of fludarabine-5´-monophosphate was decreased
upon using soluble HsdCK and increased with immobilized HsdCK (Table 2, Figure 4). In reactions
with soluble enzyme, after 18 h, fludarabine-5´-monophosphate was formed with 71%, 69%, and 60%
upon using 1 mM (3 folds), 6.5 mM (19.5 folds) and 12 mM (36 folds) fludarabine, respectively, as
opposed to 100% formation using the standard conditions. Whereas, with the immobilized HsdCK
catalyzed reactions, the formation of fludarabine-5´-monophosphate increased from 27% with the
standard reaction conditions to 47%, 37% and 55%, respectively. Using a substrate concentration of
12 mM product concentrations of 8.7 (±0.2) mM and 6.0 (±0.8) mM were measured (Table S2) for
the soluble and immobilized HsdCK, respectively. The application of the immobilized biocatalyst is
advantageous when higher substrate concentrations are applied.
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3. Discussion
Human dCK is a suitable biocatalyst for the synthesis of natural and modified
nucleoside-5’-monophosphates. After immobilization to Ni-NTA superflow, the substrate spectrum of
the immobilized HsdCK was not affected; however, the conversion percentages and the enzyme-specific
activity was decreased in comparison to the soluble enzyme. Although, ionic adsorption to charged
supports is described to be a mild way of enzyme immobilization [19], our results showed a decreased
substrate conversion percentages using low substrate concentrations. This might be explained by
mass-transfer limitations of the substrate to contact the enzyme [22] especially as the applied Ni-NTA
sepharose is a gel-like matrix. Mass-transfer limitations are widely studied applying immobilized
enzymes and served as an explanation for the lowered enzyme-specific activity [23–26]. Different
mechanisms can be responsible for these limitations. Either active sites are not accessible anymore
due to immobilization or there is a diffusional limitation which leads to gradient formation [27].
In the latter case, lower product concentrations within the matrix are observed. Interestingly, in this
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study the impact of immobilization on the percentage of conversion differed between the substrates
applied (Table 1). This might be explained by differences in the chemistry of the compounds, which is
influencing the diffusion of the substrates into the matrix.
While mass-transfer limitations negatively influence final product yields at low substrate
concentrations (Table 1), this is beneficial when higher and/or inhibitory substrate concentrations
are applied (Figure 4). For HsdCK, it was shown that dCyd is causing enzyme inhibition [28] which
might explain the decreased product formation with increasing substrate concentration (Figure 4).
A beneficial effect of immobilized biocatalysts at increasing substrate concentrations was also observed
using DmdNK [11] or invertase of Candida utilis [29] as biocatalyst. Slow diffusion of the substrate into
the matrix also served as an explanation for the reduced inhibition observed with the immobilized
biocatalyst [29].
Although reusability of the immobilized enzyme is a very attractive advantage of immobilization,
yet, a challenge is the stable attachment of the biocatalyst to the matrix. In this study, loss of activity was
observed in consecutive reactions. This is in good accordance with previous observations where protein
leach from the matrix was observed when non-covalent immobilization was applied [30]. Due to the
limitations of non-covalent binding, post-immobilization by cross-linking and covalent binding were
developed to avoid desorption of enzyme under more harsh conditions [19,31–33]. As an example, Serra
and colleagues compared different strategies to cross-link with oxidized dextran [33]. The treatment
with dextran aldehyde efficiently prevented desorption of the enzyme from the carrier. Hence, the
combination of ionic interaction with cross-linking might be a suitable option to ensures that HsdCK is
tightly bound to the matrix and that the product is not contaminated with enzymes.
For the native HsdCK, UTP was described to be the preferred phosphate donor in comparison to
ATP [20,28]. Using the heterologously expressed variant of HsdCK higher product yields were obtained
with GTP and ATP compared to UTP (Table 2). Therefore, GTP was applied as a phosphate donor in
this study. Kinetic studies with the heterologously expressed protein are, however, needed to study
inhibitory effects by increasing substrate concentrations in the presence of UTP, ATP and GTP in more
detail [28].
4. Materials and Methods
4.1. General Information
All chemicals and solvents were of analytical grade or higher and purchased, if not stated otherwise,
from Sigma-Aldrich (Steinheim, Germany), Carl Roth (Karlsruhe, Germany), TCI Deutschland
(Eschborn, Germany), Carbosynth (Berkshire, UK) or VWR (Darmstadt, Germany). All nucleobases,
nucleosides and nucleotides were purchased from Carbosynth (Berkshire, UK). 2F-AraA was purchased
from Alfa-Aesar (Kandel, Germany) with a purity of 98% and 2F-Ara-AMP from Sigma-Aldrich
(Steinheim, Germany). Ni-NTA superflow was obtained from Qiagen (Hilden, Germany). Ni-NTA
was obtained as a 50% solution. The matrix has a gel-like appearance. HPLC analyses were carried
out with an Agilent 1200 series system equipped with an Agilent DAD detector using a Phenomenex
(Torrance, CA, USA) reversed-phase Kinetex EVO C18 column (250 × 4.6 mm). The photometric assay
was carried out in 96-well white assay plates (Costar 655094, Grainer Bio-One, Kremsmünster, Austria)
using the Synergy™ Mx Multi-Mode microplate reader (Bio Tek Instruments, Winooski/Vermont,
VT, USA). Expressions strain of dCK was kindly provided by BioNukleo GmbH (Berlin, Germany).
Enzyme concentrations were determined with a NanoDrop 1000 (Thermo Fisher Scientific, Wilmington,
DE, USA).
4.2. Expression of HsdCK
Human dCK was expressed in E. coli BL21 using EnPresso B medium (Enpresso, Berlin, Germany)
based on the manufacturer´s recommendations in a volume of 50 mL. A preculture in LB medium
was inoculated from one glycerol stock of HsdCK. All three glycerol stocks used in this study were
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from the same working cell bank, which is based on one single colony. To induce protein expression,
an IPTG concentration of 50 µM was applied. Cells were harvested by centrifugation. Cells from 4
parallel expression cultures were harvested to one reaction tube. About 2 g of cell pelletwet weight were
obtained from an expression culture in 50 mL medium.
4.3. Immobilization of HsdCK
Three independent enzyme immobilizations denoted as immobilization experiments 1, 2 and 3
were performed with five replicas for each experiment (Figure S1). For each immobilization experiment,
HsdCK was freshly expressed in EnPresso B medium (4x 50 mL) from an independent glycerol stock
for each experiment.
For one immobilization experiment, 7.5 g of cell pellet were dissolved in 22.5 mL of lysis
buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 10 mM imidazole, 1 mg mL−1 lysozyme,
0.6 µg mL−1 DNase, 1 mM MgCl2 and 0.1 mg mL−1 PMSF). After the enzymatic lysis of 30 min at
30 ◦C and 300 rpm, the extract was lysed by sonification on ice for 5 min with 30% power input and
30 s on/off intervals. The extract was centrifuged afterwards at 10000 x g for 20 min, and the lysate
containing the soluble fraction of the enzyme preparation was collected.
To start the immobilization procedure, Ni-NTA superflow was activated by washing 100 µL of
Ni-NTA resin with 1 mL of lysis buffer. The washing step was repeated three times in total. Following
the matrix activation, one fifth (4.5 mL) of the lysate containing the soluble protein was loaded to
the equilibrated Ni-NTA matrix in 3 successive steps (each 1.5 mL). For each step, the Ni-NTA resin
and the lysate were incubated at room temperature for 60 mins, followed by brief centrifugation to
remove the supernatant. Following the loading, the matrix was washed three times, each with 1 mL
washing buffer (50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 20 mM imidazole) to remove
any non-specifically bound enzyme.
Two out of five replicates for each immobilization experiment were used for protein elution.
The bound protein was eluted three times (E1, E2, E3), each with 100 µl of elution buffer (50 mM
sodium phosphate (pH 8.0), 300 mM NaCl and 250 mM imidazole). The volume of the elution buffer
was determined based on preliminary experiments (Figure S2).
Human dCK was dialyzed against 50 mM Tris-HCl (pH 7.4). The protein purity was checked
by SDS-PAGE according to a standard protocol [34], and enzyme concentrations were determined
with NanoDrop 1000 (Thermo Fisher Scientific, Wilmington, DE, USA) at a wavelength of 280 nm.
As negative controls, elution buffer and binding buffer were used. Protein concentrations were
determined using an extinction coefficient value calculated based on the amino acid composition of
HsdCK (ε280 nm = 56380 M−1 cm−1). To guarantee that imidazole is not interfering with measurements
at 280 nm, the absorbance of the applied solutions was analyzed by NanoDrop using deionized water
as blank (Figure S5). Imidazole was showing no absorbance in the concentrations applied in this study.
Standard deviations were calculated from two replicas of the respective immobilization experiment.
4.4. Standard Enzymatic Assay
The following conditions were set as the standard for the whole study. In a final volume of
1 mL a reaction mixture containing 0.333 mM nucleoside (substrate), 0.4 mM phosphate donor
(GTP), 0.01 mg mL−1 HsdCK and 10 mM MgCl2 in 2 mM potassium phosphate buffer (IUPAC name:
Potassium dihydrogen phosphate; dipotassium hydrogen phosphate) (pH 7) was incubated at 37 ◦C
with continuous horizontal shaking at 200 rpm. The reactions were started by the enzyme addition
(immobilized or soluble). At defined time points, samples were taken for further analysis (photometric
assay or HPLC). For the photometric assay, samples were stored on ice until further usage. For HPLC
analysis, samples were transferred to an equal volume of methanol. After centrifugation at 215,000× g
for 10 min, the supernatant was analyzed by HPLC.
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4.5. Screening of the Substrate Spectrum of Soluble and Immobilized HsdCK
The screening assay was performed to get a qualitative impression on the substrate spectrum
of heterologously expressed HsdCK in the soluble and immobilized form. For the screening, seven
natural and 11 modified nucleoside analogues were used as substrates in a reaction volume of 0.5 mL.
Before the reaction was started, the three replicas of immobilization experiment 3 were pooled. The
reactions were performed in duplicates. The negative control was prepared and incubated in the
same manner without the addition of the enzyme to ensure the substrates’ stability under the reaction
conditions. The phosphorylation of the nucleosides was determined after 20 h incubation to guarantee
that product formation is observed with also poor substrates. The photometric assay was applied as
described below to quantify product formation based on the depletion of GTP. Standard deviations
were calculated from two in independent experiments.
4.6. Determination of Specific Activities for NMP Analogues
NMP analogues of cladribine, clofarabine and fludarabine were synthesized under standard
conditions in a total volume of 1 mL for 1 h using soluble and immobilized HsdCK. Regular samples
were taken to observe a linear depletion of the phosphate donor GTP. Samples were analyzed using the
photometric assay as described below. Standard deviations were calculated from two (soluble enzyme)
and three (immobilized enzyme) in independent experiments.
The retained activity was calculated from the quotient of the specific activity of the immobilized
enzyme to the free enzyme (Equation (1)).
Retained activity [%] =
specific activity of the immobilized enzyme [U/mg]
specific activity of the soluble enzyme [U/mg]
× 100% (1)
The conversion percentages were calculated based on GTP depletion. One unit (U) of enzyme
activity was defined as the amount of enzyme required for the conversion of 1 µmol substrate per
minute under the given reaction conditions.
4.7. Optimization of Reaction Conditions
To investigate parameters influencing the reaction yield, different conditions, including the
phosphate donor and its ratio to the substrate and the MgCl2 were examined (Table 2). All reactions
were performed with fludarabine in a 1 mL volume for 1 h. Before the reaction was started, the three
replicas of immobilization experiment 3 were pooled. The reactions were performed in duplicates.
To evaluate the efficiency of different phosphate donors, ATP, GTP and UTP were used alternatively
under standard reaction conditions.
The ratio of phosphate donor to the substrate was as well tested. Ratios of 1:1, 1:2 and 1:4
fludarabine to GTP were used. While maintaining all reaction conditions as the standard reaction,
fludarabine concentration was decreased from 0.4 to 0.2 and 0.1 mM.
The effect of different MgCl2 concentration was investigated by applying different ratios of
phosphate donor (GTP) to MgCl2. MgCl2 with concentrations of 0.4 mM, 1 mM and 2 mM were used
in the standard reaction.
For all the reactions, samples were taken over 1 h with 10 minutes intervals and analyzed using
the photometric assay as described below. Standard deviations of the reactions catalyzed by the soluble
enzyme were calculated from two independent experiments.
4.8. Increasing the Substrate Concentration for Fludarabine-5´-Monophosphate Synthesis
The concentrations of fludarabine (0.333 mM), GTP (0.4 mM) and HsdCK (0.01 mg mL−1) were
increased by a factor of 3, 19.5, or 36 times, while maintaining the ratio of fludarabine to GTP (1:1.2)
and that of fludarabine to HsdCK (1:0.03). 1 mM, 6.5 mM and 12 mM fludarabine were used with
1.2 mM, 7.8 mM and 14.4 mM GTP, respectively, in the presence of 0.03 mg mL−1, 0.195 mg mL−1 and
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0.36 mg mL−1 HsdCK, respectively. Reactions were performed in a final volume of 0.1 mL in 2 mM
potassium phosphate buffer (pH 7) containing 10 mM MgCl2. After 18 h, reactions were analyzed by
HPLC as described below. Standard deviations were calculated from two independent experiments.
4.9. Reusability of the Immobilized Enzyme
1 mL standard reaction using fludarabine as substrate and immobilized HsdCK was incubated
at 37 ◦C. After 3 h, the enzyme was collected by centrifugation at 500 rpm for 5 min and re-used.
Immobilized HsdCK was used for three consecutive reactions denoted by R1, R2 and R3. Samples were
analyzed using HPLC as described below. Standard deviations were calculated from triplicate reactions.
The relative retained activity used to study the reusability of HsdCK was calculated based
on Equation (2).
Relative retained activity [%] =
% of formation of fludarabine− 5′ −monophosphate in
consecutive reactions
mean value for % of formation of fludarabine− 5′−
monophosphate in the first rection
× 100%
(2)
4.10. Photometric Assay
The formation of NMPs was detected photometrically using the Kinase-Glo® Max assay (Promega,
Madison/Wisconsin, USA). The assay is used to quantify product formation based on the depletion
of GTP. Samples were taken from the reaction at different time points and stored on ice until further
analysis. In a 96-well plate, 10 µL of Kinase-Glo® reagent was added to 10 µL of each sample and
80 µL deionized water. After 10 min of incubation in the dark, luminescence was measured for 1s over
an extended dynamic range. The conversion percentages of nucleosides to NMPs were calculated
based on the nucleotide (phosphate donor) depletion.
4.11. High Performance Liquid Chromatography (HPLC)
Nucleoside/nucleotide depletion and nucleotide formation were validated by HPLC (λ = 260 nm)
using a reversed-phase Kinetex EVO C18 column at 34 ◦C with a flow rate of 1 mL min−1. Substrates
and products were identified by comparing their retention times with those of authentic standards.
Quantification was performed using a 6-step calibration in the range from 0 mM to 1 mM over the
peak area.
Gradual elution was performed using eluent A (8 mM tetrabutylammonium bisulfate in 100 mM
potassium phosphate buffer, pH 5.4) and eluent B (70% eluent A and 30% methanol). The following
gradient was used: After 10 min of 80% A and 20% B, a gradual change to 40% A and 60% B over
10 min, then to 38% A and 62% B over 12 min. The initial condition (80% A and 20% B) was restored
within 1 min and maintained for 3 min.
The following retention times were observed: GMP, 4.4 min; 2F-Ade, 6.5 min; GDP, 9.3 min;
2F-AraA, 10.6 min; 2F-Ara-AMP, 19.4 min; GTP, 22.1 min. Yields were determined according to Equation
(3). Standard deviations were calculated from three independent experiments unless otherwise specified.
Reaction yield [%] =
conc.of the formed nucleotide [mM]
conc.of the formed nucleotide [mM] + conc of nucleoside [mM]
× 100%. (3)
5. Conclusions
Like its natural variant heterologously expressed HsdCK accepts a wide variety of deoxyribonucleosides
and their analogues as substrates. The immobilization onto Ni-NTA superflow is a suitable option
to enhance the purification process by allowing the buffer system to be changed easily and
allowing the reusability of the enzyme. Although activities of the immobilized HsdCK were lower
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compared to the soluble enzyme at low enzyme concentration, activity significantly increased
with increasing substrate concentration. Hence, this study shows that HsdCK is a valuable
biocatalyst for the synthesis of a wide range of high-added value NMP analogues, including
fludarabine-5’-monophosphate, cladribine-5’-monophosphate and clofarabine-5’-monophosphate
under industrially-relevant conditions. Furthermore, immobilized HsdCK can be used to study the
efficient phosphorylation of new drug candidates in in vitro screening assays.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/9/12/997/s1.
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